Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 118 filers reported holding Y-MABS THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,041,909 | -19.7% | 191,176 | 0.0% | 4.24% | +3.5% |
| Q2 2023 | $1,298,276 | +35.5% | 191,176 | 0.0% | 4.10% | +39.5% |
| Q1 2023 | $957,792 | +2.7% | 191,176 | 0.0% | 2.94% | -4.6% |
| Q4 2022 | $932,939 | -66.2% | 191,176 | 0.0% | 3.08% | -67.2% |
| Q3 2022 | $2,757,000 | -4.7% | 191,176 | 0.0% | 9.37% | -1.9% |
| Q2 2022 | $2,892,000 | +27.3% | 191,176 | 0.0% | 9.56% | +263.4% |
| Q1 2022 | $2,271,000 | -26.7% | 191,176 | 0.0% | 2.63% | +35.1% |
| Q4 2021 | $3,099,000 | -49.9% | 191,176 | -11.9% | 1.95% | -49.5% |
| Q3 2021 | $6,191,000 | -15.6% | 216,916 | 0.0% | 3.86% | -19.5% |
| Q2 2021 | $7,332,000 | +11.8% | 216,916 | 0.0% | 4.79% | +18.6% |
| Q1 2021 | $6,560,000 | -38.9% | 216,916 | 0.0% | 4.04% | -11.1% |
| Q4 2020 | $10,740,000 | – | 216,916 | – | 4.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 216,916 | $6,191,000 | 3.86% |
| Sofinnova Investments, Inc. | 2,194,278 | $62,625,000 | 3.71% |
| MPM BioImpact LLC | 452,970 | $12,928,000 | 2.00% |
| Soleus Capital Management, L.P. | 265,700 | $7,583,000 | 1.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 452,110 | $12,903,000 | 1.17% |
| ORACLE INVESTMENT MANAGEMENT INC | 315,642 | $9,008,000 | 1.12% |
| First Light Asset Management, LLC | 577,663 | $16,487,000 | 1.09% |
| Lombard Odier Asset Management (Switzerland) SA | 352,839 | $10,070,000 | 0.62% |
| Cormorant Asset Management, LP | 500,000 | $14,270,000 | 0.58% |
| Artal Group S.A. | 400,000 | $11,416,000 | 0.26% |